X

Trial Profile

Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alendronic acid (Primary)
Indications Coronary artery restenosis
Focus Therapeutic Use
Acronyms BLADE; BLADE-PCI
Sponsors BIOrest

Most Recent Events

16 Mar 2022 Primary endpoint (%NIH volume) has not been met according to the results published in the American Heart Journal
16 Mar 2022 Results published in the American Heart Journal
10 Jan 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com